Ideaya Biosciences: Key Pivotal Data Imminent

Galzus Research3.26K FollowersFollow5ShareSavePlay(10min)CommentsSummaryIdeaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate.IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding pipeline targeting multiple high-value oncology indications.Darovasertib has shown promising efficacy as both monotherapy and in combination, with phase 3 data expected imminently and potential for FDA approval.Despite aggressive valuation and rising cash burn, I maintain a Buy rating, confident in IDYA's strategic positioning and clinical potential. Maki Nakamura/DigitalVision via Getty Images Topline Summary and Update I've been on record as an optimist on the outlook for IDEAYA Biosciences (IDYA) starting around last year, due in large part to the untapped potential ofThis article was written byGalzus Research3.26K FollowersFollowI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.